Charles Zhu
Stock Analyst at Guggenheim
(2.72)
# 1,853
Out of 5,182 analysts
19
Total ratings
52.94%
Success rate
29.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNGX Tango Therapeutics | Maintains: Buy | $10 → $12 | $26.64 | -54.95% | 4 | Oct 24, 2025 | |
| CBIO Crescent Biopharma | Initiates: Outperform | $22 | $21.28 | +3.38% | 1 | Jun 18, 2025 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $3.46 | +246.82% | 4 | Nov 7, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $107.61 | -47.96% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $5.44 | +304.41% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $37.25 | -30.20% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $33.91 | -5.63% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $27.80 | -49.64% | 2 | May 5, 2022 |
Tango Therapeutics
Oct 24, 2025
Maintains: Buy
Price Target: $10 → $12
Current: $26.64
Upside: -54.95%
Crescent Biopharma
Jun 18, 2025
Initiates: Outperform
Price Target: $22
Current: $21.28
Upside: +3.38%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $3.46
Upside: +246.82%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $107.61
Upside: -47.96%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $5.44
Upside: +304.41%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $37.25
Upside: -30.20%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $33.91
Upside: -5.63%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $27.80
Upside: -49.64%